Published in CNS Drug Rev on January 01, 2003
Biological substrates of reward and aversion: a nucleus accumbens activity hypothesis. Neuropharmacology (2008) 2.80
Dynorphin, stress, and depression. Brain Res (2009) 2.45
Kappa-opioid ligands in the study and treatment of mood disorders. Pharmacol Ther (2009) 1.42
Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats. Biol Psychiatry (2011) 1.33
Altered sensitivity to rewarding and aversive drugs in mice with inducible disruption of cAMP response element-binding protein function within the nucleus accumbens. J Neurosci (2009) 1.30
Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats. Neuropharmacology (2011) 1.29
Hypothesis-driven medication discovery for the treatment of psychostimulant addiction. Curr Drug Abuse Rev (2008) 1.26
Brain reward regulated by AMPA receptor subunits in nucleus accumbens shell. J Neurosci (2006) 1.17
Effects of kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats. Psychopharmacology (Berl) (2010) 1.14
Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans. Biol Psychiatry (2012) 1.04
Effects of peripherally restricted κ opioid receptor agonists on pain-related stimulation and depression of behavior in rats. J Pharmacol Exp Ther (2011) 1.03
Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats. Psychopharmacology (Berl) (2010) 1.00
The role of kappa-opioid receptor activation in mediating antinociception and addiction. Acta Pharmacol Sin (2010) 0.95
Does the kappa opioid receptor system contribute to pain aversion? Front Pharmacol (2014) 0.92
Evaluation of opioid modulation in major depressive disorder. Neuropsychopharmacology (2014) 0.92
ΔFosB enhances the rewarding effects of cocaine while reducing the pro-depressive effects of the kappa-opioid receptor agonist U50488. Biol Psychiatry (2011) 0.91
The effects of repeated opioid administration on locomotor activity: I. Opposing actions of mu and kappa receptors. J Pharmacol Exp Ther (2009) 0.90
Ligand directed signaling differences between rodent and human κ-opioid receptors. J Biol Chem (2012) 0.88
Effects of ketoprofen, morphine, and kappa opioids on pain-related depression of nesting in mice. Pain (2015) 0.87
Ligand-directed functional selectivity at the mu opioid receptor revealed by label-free integrative pharmacology on-target. PLoS One (2011) 0.85
Association of the PDYN gene with alcohol dependence and the propensity to drink in negative emotional states. Int J Neuropsychopharmacol (2012) 0.85
Kappa-opioid receptor signaling in the striatum as a potential modulator of dopamine transmission in cocaine dependence. Front Psychiatry (2013) 0.84
Pharmacological activation of kappa opioid receptors: aversive effects in adolescent and adult male rats. Psychopharmacology (Berl) (2013) 0.83
A single injection of a novel κ opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in rats. Behav Pharmacol (2012) 0.80
A variant on the kappa opioid receptor gene (OPRK1) is associated with stress response and related drug craving, limbic brain activation and cocaine relapse risk. Transl Psychiatry (2013) 0.79
Anti-nociception mediated by a κ opioid receptor agonist is blocked by a δ receptor agonist. Br J Pharmacol (2014) 0.79
Translational pharmacokinetic-pharmacodynamic modelling; application to cardiovascular safety data for PF-00821385, a novel HIV agent. Br J Clin Pharmacol (2010) 0.79
Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects. J Med Chem (2014) 0.78
The mu/kappa agonist nalbuphine attenuates sensitization to the behavioral effects of cocaine. Pharmacol Biochem Behav (2013) 0.78
Virus-mediated shRNA knockdown of prodynorphin in the rat nucleus accumbens attenuates depression-like behavior and cocaine locomotor sensitization. PLoS One (2014) 0.78
A Trigger for Opioid Misuse: Chronic Pain and Stress Dysregulate the Mesolimbic Pathway and Kappa Opioid System. Front Neurosci (2016) 0.77
PDYN rs2281285 variant association with drinking to avoid emotional or somatic discomfort. PLoS One (2013) 0.77
Nociceptin/orphanin FQ blocks the antinociception induced by mu, kappa and delta opioid agonists on the cold water tail-flick test. Eur J Pharmacol (2006) 0.77
Kappa Opioid Receptor Agonist and Brain Ischemia. Transl Perioper Pain Med (2014) 0.77
Novel κ-opioid receptor agonist MB-1C-OH produces potent analgesia with less depression and sedation. Acta Pharmacol Sin (2015) 0.76
Behavioral Characterization of Kappa Opioid Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats. J Pharmacol Exp Ther (2016) 0.75
In Vitro and In Vivo Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential. Front Psychiatry (2017) 0.75